AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. secured $37 million in Series A financing led by InnoPinnacle Fund to advance AHB-137 clinical development for HBV cure.

Jul 15, 2024•over 1 year ago

Amount Raised

$37 Million

Round Type

series a

San MateoBiotechnologyHealth Care

Investors

Genesis CapitalHankang CapitalQiming Venture PartnersYuanbio Venture CapitalInno Pinnacle Fund

Description

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. announced the completion of a $37 million Series A financing round to further support the clinical development of AHB-137, their lead product candidate, and advance their proprietary Med-Oligo™ technology platform and product pipelines.

Company Information

Company

AusperBio

Location

San Mateo, California, United States

About

AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus on curing chronic hepatitis B. The company has developed a proprietary Med-OligoTM ASO platform with novel insights into ASO design and capabilities to substantially enhance the current ASO therapeutics. Combining with efficient targeted delivery conjugation technologies, the modular Med-OligosTM Platform empowers ASO therapeutics to treat broad viral infections, metabolic conditions, genetic disorders, and immune diseases.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends